Nuvectis Pharma Stock Forecast
NASDAQ: NVCTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
NVCT analyst consensus
Consensus (6 analysts)
strong_buy
Avg. price target
$35.40+74.47%
- Strong buy 2
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 6 Wall Street analysts covering Nuvectis Pharma (2026-10-08), 6 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $35.40, with a high estimate of $40.00 and a low estimate of $30.00. The average target implies upside of 74.5% from the current price of $20.29.
The spread between the highest and lowest targets is 33.3%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for NVCT.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 33% |
| Buy | 4 | 67% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $30.00 | +47.86% |
| Average target | $35.40 | +74.47% |
| High target | $40.00 | +97.14% |